Edaravone: A new drug approved for ALS

Cell

Volumn 171, Issue 4, 2017, Pages 725-

  Rothstein, Jeffrey D ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORPHENAZONE; AMINO ACID RECEPTOR BLOCKING AGENT; PHENAZONE; PHENYLMETHYLPYRAZOLONE; RILUZOLE;

AMYOTROPHIC LATERAL SCLEROSIS; DRUG APPROVAL; DRUG DEVELOPMENT; DRUG EFFECT; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; PRIORITY JOURNAL; SHORT SURVEY; TREND STUDY; ANALOGS AND DERIVATIVES;

AMYOTROPHIC LATERAL SCLEROSIS; ANTIPYRINE; DRUG APPROVAL; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RILUZOLE;

EID: 85032709603     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.10.011     Document Type: Short Survey

References (6)

1. Brown, R.H., Al-Chalabi, A., Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 377 (2017), 162–172.
2. Haeusler, A.R., Donnelly, C.J., Rothstein, J.D., The expanding biology of the C9orf72 nucleotide repeat expansion in neurodegenerative disease. Nat. Rev. Neurosci. 17 (2016), 383–395.
3. Sawada, H., Clinical efficacy of edaravone for the treatment of amyotrophic lateral sclerosis. Expert Opin. Pharmacother. 18 (2017), 735–738.
4. Takei, K., Watanabe, K., Yuki, S., Akimoto, M., Sakata, T., Palumbo, J., Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Frontotemporal Degener. 18:sup1 (2017), 5–10.
5. Taylor, J.P., Brown, R.H. Jr., Cleveland, D.W., Decoding ALS: from genes to mechanism. Nature 539 (2016), 197–206.
6. Writing, G., Edaravone, A.L.S.S.G. Writing Group, Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 16 (2017), 505–512.